Office scene with a man at a desk, surrounded by papers, and a text overlay announcing a new blog post about when descriptions need to change.

Dennemeyer Group

06 octobre 20265 minutesEveryday IP

G 1/25: When must the description be adapted to amended claims?

On 3 September 2026, the Enlarged Board of Appeal of the European Patent Office issued its decision in G 1/25 “Hydroponics”, clarifying a long-debated question in European patent practice: when claims are amended, must the description also be adapted?

The Enlarged Board held that an inconsistency between amended claims and the description or drawings must be addressed if it results in non-compliance with a requirement of the European Patent Convention (EPC). However, the EPC does not directly and explicitly require applicants to amend the description merely to achieve formal consistency with the amended claims.


Why does G 1/25 matter?

Practitioners welcome G 1/25 as it lies at the heart of a very practical debate between applicants working together with their patent attorneys, and EPO examiners: after narrowing the claims, how much of the description must be rewritten? For years, applicants invested significant time, effort, and money adapting sometimes lengthy descriptions, despite the EPC containing no explicit requirement for perfect concordance.

We observe that in about 80 % of EP patent applications, claims evolve during examination, potentially several times. An applicant may narrow them to distinguish the invention from prior art, while the description still contains broader definitions or embodiments from the original application.

This had led to diverging approaches in EPO case law. Some Boards considered Article 84 EPC to provide a basis for requiring the description to be brought into line with amended claims. Others considered that the mere presence of unclaimed subject matter in the description did not necessarily prevent grant.

The Enlarged Board provides the following answer in G 1/25: what matters is not the existence of a difference between the claims and the description, but if this difference leads to non-compliance with the EPC.

A simple example

Consider the following hypothetical example:

A patent application originally claims a product comprising feature A or feature B. During examination, the claim is narrowed to a product comprising feature A.

The description still contains an embodiment directed to a product comprising feature B.

Does that example have to be deleted?

Not necessarily. If it is clear to the skilled person that the feature B embodiment simply falls outside the amended claim, its presence alone does not require adaptation.

The situation is different if the description states that, for the purposes of the invention, the term “feature A” also includes feature B or that feature A is an alternative to feature B. This could create genuine uncertainty as to how the amended claim should be understood.

In that case, the inconsistency may affect compliance with the EPC and would need to be addressed.

Interestingly, according to G 1/25, the embodiment comprising feature B might not be relevant only for determining whether the description should be adapted. According to point 38 of the decision, the technical teaching contained in the description may, in some circumstances, be relevant to the assessment of inventive step. Thus, even if the embodiment comprising feature B clearly falls outside the amended claims and does not create any inconsistency for the purposes of Article 84 EPC, it could still become relevant if its technical content affects the evaluation of the inventive contribution of the claimed invention. This observation reinforces the idea that the description is not merely a background document for claim interpretation but may itself play an active role in the assessment of compliance with EPC requirements.

This key aspect of G 1/25 provides an important missing piece of the legal certainty required for assessing description adaptation, while also highlighting that the relevance of the description may extend beyond issues of formal consistency.

G 1/25 and claim interpretation

The decision should also be read alongside G 1/24, in which the Enlarged Board held that the description and drawings must always be consulted when interpreting claims for the assessment of patentability under Articles 52 to 57 EPC, reinforcing the central importance of the description and drawings.

G 1/25 nevertheless rejects the idea that the description must simply mirror the claims. Examples or embodiments outside the amended scope of the claims do not automatically have to be removed.

A statement left in the description can potentially affect how an amended claim is interpreted under the EPC. As a reminder, iterative claim amendments may confer upon the independent claim a meaning that becomes more complex to ascertain.
This also means that description amendments themselves acquire greater significance. Removing or modifying explanatory passages may affect the way claims are construed in later opposition or potentially, in national revocation or infringement proceedings, where the principles of G 1/24 and G 1/25 may prove influential. This is particularly relevant in light of T 439/22, where amendments to the description ultimately became central to the assessment of compliance with Article 123 EPC. Description adaptation can therefore no longer be regarded as a purely administrative exercise, but should be assessed carefully in view of its potential impact on both claim interpretation and future post-grant challenges.

What does this mean in practice?

Following a significant claim amendment, applicants and patent owners should review the description and drawings with three questions in mind:

  1. How has the meaning of the amended claims evolved?

  2. Does the interpretation of the description or the drawings trigger an inconsistency with the amended claims?

  3. Could that inconsistency affect compliance with the EPC?

If so, adaptation will be required. If a passage merely describes subject matter that is no longer claimed, without creating a legally relevant inconsistency, G 1/25 does not impose a general obligation to remove it. As is apparent from the above, the concept of “inconsistency” endorses a central role. Interestingly, the decision extensively discusses this concept to provide some useful guidance.

Particular attention should be paid to situations where the skilled person could be left in “real doubt” as to the meaning of a claim or as to whether a specific embodiment falls within its scope. The Enlarged Board identifies these situations as examples of inconsistency. However, the precise boundary between a mere clarity issue and a legally relevant inconsistency remains uncertain and will likely require further clarification through future case law. In this respect, G 1/25 does not resolve all questions concerning the relationship between claims and description. It will be interesting to see whether the forthcoming G 1/26 decision provides any further guidance on related aspects of claim interpretation and on the circumstances in which the description may influence the understanding of claim language.

Key takeaways

G 1/25 confirms that description adaptation is a substantive, not merely formal, exercise.

Applicants and patent owners should therefore avoid both extremes: leaving potentially problematic inconsistencies untouched, but also mechanically deleting every embodiment or statement that falls outside amended claims. Superfluous excision from the description may affect claim interpretation, enforcement, or validity assessments at a later stage. Determining the appropriate extent of description adaptation therefore requires careful review by a patent attorney.

For companies managing European patent portfolios, the decision is a good reason to review prosecution practices. Significant claim amendments should trigger a focused review of the description and drawings to identify inconsistencies that could have real consequences under the EPC. The objective is not to achieve a perfectly “clean” description, but to ensure that the description does not undermine the legal position established by the amended claims.


View EPO decision

06 octobre 20265 minutesEveryday IP
Cyrille Rousseau - European Patent Attorney
Head of European Patent Practice

Cyrille Rousseau

Groupe Dennemeyer
55, rue des Bruyères 1274 Howald, Luxembourg
219082198015
www.linkedin.com/in/cyrille-rousseau-7077a28a/
Cyrille Rousseau - European Patent Attorney

Cyrille Rousseau met son expertise au service d’entreprises des secteurs de l’automobile, du spatial, de l’aéronautique, et notamment de l’hélicoptère. Parallèlement, il accompagne diverses start-ups ainsi que des instituts de recherche.

Il est responsable d’inventions dans les domaines de la mécanique, de la physique, de l’électronique, de l’informatique, et plus particulièrement de l’apprentissage automatique (ML, DL). Cyrille Rousseau possède une solide expérience en rédaction de brevets et en procédures de délivrance devant l’OEB. Plusieurs clients lui confient également des oppositions ainsi que des observations de tiers devant l’OEB.

Membre de l’AIPPI, il participe au comité permanent dédié aux technologies de l’information et à Internet, où il se concentre sur les questions liées à l’intelligence artificielle. Il est également délégué du groupe de normalisation du Luxembourg (ILNAS) dans le domaine de l’IA.

Passionné de photographie, il porte une attention particulière aux détails pour proposer des interprétations originales des images.

Cyrille Rousseau parle anglais, allemand et français.

Maria Paola Pace Napoleone - Italian Patent Attorney
Italian Patent Attorney

Maria Paola Pace Napoleone

Groupe Dennemeyer
Via Giulio Caccini 1 00198 Rome
[email protected]
219082198015
Maria Paola Pace Napoleone - Italian Patent Attorney

Paola s'est principalement concentrée sur les procédures de dépôt et de traitement des demandes de brevet dans les domaines des sciences de la vie et de la chimie en général.

Avant de rejoindre le secteur de la PI, elle a passé environ 20 ans en tant que chercheuse dans des laboratoires universitaires et industriels, tant dans de grandes sociétés pharmaceutiques que dans des CRO. En tant que chimiste médicinale, elle a fait partie d'équipes travaillant sur des projets de découverte de médicaments antiviraux, anticancéreux et cardiovasculaires, et a contribué à la mise sur le marché de deux médicaments approuvés pour les patients. Elle a également acquis de l'expérience en gestion de projets scientifiques pour des projets de recherche intégrés et multi-parties prenantes. Elle est l'auteur de plus de 40 publications scientifiques et inventeur dans 7 familles de brevets.

Elle s'occupe des procédures relatives aux brevets nationaux, européens et étrangers, fournit des avis sur la brevetabilité, la contrefaçon, la liberté d'exploitation et la diligence raisonnable. Elle a également acquis une expérience technique-juridique pour aider les clients dans la rédaction et l'analyse d'accords de licence, de protocoles d'accord, d'accords de confidentialité, d'accords de transfert de matériel, et autres.

Maria Paola Pace Napoleone parle anglais et italien et travaille dans le domaine de la propriété intellectuelle depuis 2011.